News

Every breakthrough in blood cancer treatment starts with a question.

Can we diagnose blood cancer earlier? Can we develop more effective treatments? Can we reduce side effects? Can we prevent relapse? Can we improve quality of life and help people live longer?

The answers are the results of years of scientific discovery, collaboration and carefully conducted clinical trials involving researchers, health professionals and participants working towards a common goal.

This World Cancer Research Day, the Australasian Leukaemia and Lymphoma Group (ALLG) celebrates the research we have designed and conducted that has transformed global blood cancer treatment and care through significant impactful trials.

Support Research, Save Lives

Research is Changing the Future

Over the past few decades, blood cancer research has changed how blood cancers are diagnosed and treated. Researchers have developed more targeted therapies that attack cancer cells more precisely, immunotherapies that use the body’s own immune system, and more personalised treatment approaches based on the genetic characteristics of an individual’s disease.

A powerful example is Chronic Myeloid Leukaemia (CML), where the work of ALLG’s South Australia’s CML research teams has helped change a once-fatal disease into one where many patients can now expect a near-normal life expectancy. Through more than three decades of collaboration between clinicians, laboratory researchers and the ALLG clinical trials program, their research has contributed to advances in molecular testing, targeted therapies and international treatment guidelines, benefiting more than 1,300 patients through clinical trial participation and helping shape CML care worldwide.

Research is helping us answer some of the biggest challenges in blood cancer, including why some patients respond well to treatments and others do not, how to detect early relapse sooner, and how to develop more effective and less toxic treatments.

Next Generation of Blood Cancer Research

Clinical blood cancer trial research is entering an exciting new phase.

Platform trials are at the forefront of this approach, allowing multiple therapies to be evaluated within a single study and rapidly adapting to new scientific discoveries. ALLG’s AMLM26 INTERCEPT and AMLM28 ADAPT, and MDS05 MESSAGE trials are examples of this next generation of research, helping to identify more effective, personalised treatment options and bringing promising new therapies to patients faster than ever before.

Clinical trial research is driving significant progress in blood cancer, but there is still much more work to do. Many blood cancers remain difficult to treat, and too many patients continue to experience relapse or have limited treatment options. Continued investment in clinical trial research is essential if we are to overcome these challenges.

As Australasia’s only not-for-profit collaborative blood cancer clinical trials group, ALLG brings together clinicians, researchers, patients and partners to turn scientific discoveries into real-world advances in care. On World Cancer Research Day, we celebrate the collective efforts of the research community and the patients who participate in clinical trials, helping to shape a future where more people can live longer, healthier lives after a blood cancer diagnosis.

Support Research, Save Lives